New Delhi, 10 October 2025: ENTOD Pharmaceuticals, a global leader in eye health innovation, has announced the launch of OCUBIOME™, India’s first ocular probiotic blend designed specifically for maintaining healthy eyes. The proprietary formulation has been developed at the company’s state-of-the-art R&D facility in Navi Mumbai.
Addressing Modern Eye Health Challenges
With today’s screen-heavy lifestyles and increasing corrective eye surgeries, issues such as dry eye syndrome, ocular discomfort, and digital eye strain are becoming increasingly common. Millions experience symptoms like burning eyes, blurred vision, and post-surgical discomfort daily.
While existing lubricating therapies offer temporary relief, there is a growing need for holistic, long-term care. OCUBIOME™ aims to bridge this gap by restoring the ocular and gut microbiota balance, enhancing both immediate comfort and sustained ocular health.
A Convenient, Science-Backed Innovation
Delivered in mouth-melting, no-added-sugar sachets, OCUBIOME™ fits effortlessly into a once-daily routine, supporting:
-
Ocular comfort
-
Recovery from digital eye strain
-
Long-term eye wellness
“Eye health today cannot be addressed in isolation – it is impacted by lifestyle, environment, and recovery needs after surgery. With OCUBIOME™, ENTOD is introducing a category-first innovation that brings freshness and convenience to how we manage ocular wellness,” said Mr. Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals.
The Science Behind the Innovation
“Ocular health must be considered within the broader systemic context. Evidence shows that the gut microbiome plays a direct role in ocular inflammation and disease progression. ENTOD’s probiotic innovation provides clinicians with a scientifically supported option to improve outcomes in conditions such as dry eye and post-surgical recovery,” said Dr. Hitesh Chheda, Medical Director, Asian Eye Institute & Laser Centre.
A New Era in Preventive Eye Care
The launch of OCUBIOME™ marks a turning point in preventive eye care. As awareness grows around the gut–eye axis, this innovation paves the way for proactive management of eye health, offering patients more than just symptomatic relief.
OCUBIOME™ will be available by prescription from ophthalmologists starting November 2025.
About ENTOD Pharmaceuticals
ENTOD Pharmaceuticals is a global, research-driven pharmaceutical company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2,000+ member global team, and a presence in 67 countries, ENTOD upholds the highest international GMP and European-certified quality standards.
